1. The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer
- Author
-
Jingya Zhao, Xin Ye, Liang Xue, Deming He, Yunshan Tan, Chen Xu, Nuo Xu, Qun Wang, Yingyong Hou, Sujie Akesu, Xin Zhang, Xiaoying Wang, Haiying Zeng, Jie Huang, Guanshan Zhu, Shaohua Lu, and Qunying Hong
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.disease_cause ,Antibodies ,Disease-Free Survival ,Egfr tki ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,Epidermal growth factor receptor ,Lung cancer ,Protein Kinase Inhibitors ,Aged ,Aged, 80 and over ,Mutation ,Hematology ,biology ,Kinase ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,respiratory tract diseases ,ErbB Receptors ,Gene Expression Regulation, Neoplastic ,Specific antibody ,Cancer research ,biology.protein ,Female ,Non small cell ,business - Abstract
We aimed to quantify the epidermal growth factor receptor (EGFR) mutation in tumors and to analyze its prediction of EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment efficacy in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients.We examined EGFR mutation status in 124 lung cancer samples by direct sequencing and amplification refractory mutation system. Among them, 41 were appropriate to quantify the expression of mutant EGFR proteins using immunohistochemistry (IHC) with mutation-specific antibodies. The quantification was determined by both the staining intensity and the proportion of stained tumor cells.The median progression-free survival (PFS) in patients with a high score for mutant EGFR expression was 18.0 months (95 % CI 16.0-20.0), which was significantly longer than that in patients with a low score (8.0 months; 95 % CI 2.6-13.4; P = 0.048). Such significant association with patients' PFS was also apparent in the proportion of stained tumor cells (median, 19.0 vs. 8.0 months; P = 0.019), but not in the staining intensity (P = 0.787). Among the 41 specimens, 32 were detected EGFR mutation positive by both direct sequencing and ARMS, referring to a relatively high abundance of mutation, and 26 (81.3 %) of them gained a high expression score of mutant proteins as well. Six samples with mutation negative by direct sequencing but positive by ARMS, which showed a low abundance, and 5 (83.3 %) of them also revealed a low expression score. The EGFR mutation quantitative analysis using mutation-specific IHC was moderately consistent with that by molecular-based assays (P = 0.001, kappa value 0.50).Our results suggest that immunohistochemical analysis with mutation-specific antibodies is a promising approach for quantifying EGFR mutations, and may predict the effect of EGFR-TKI treatment for EGFR mutation-positive NSCLC.
- Published
- 2014